<DOC>
	<DOCNO>NCT00049686</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness VNP40101M treat patient relapsed refractory leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>VNP40101M Treating Patients With Relapsed Refractory Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect VNP40101M patient relapse refractory leukemia poor-risk myelodysplastic syndrome . - Determine maximum tolerate dose drug patient . - Determine pharmacokinetics drug patient . - Determine antitumor effect drug patient . OUTLINE : Patients receive VNP40101M IV 15 minute every 4 week . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Relapsed refractory leukemia standard therapy anticipate result durable remission OR Poorrisk myelodysplastic syndrome PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No symptomatic coronary artery disease No uncontrolled arrhythmia No uncontrolled congestive heart failure Other No uncontrolled active infection PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow Chemotherapy At least 2 week since prior myelosuppressive cytotoxic chemotherapy absence rapidly progress disease At least 48 hour since prior hydroxyurea Endocrine therapy Not specify Radiotherapy Prior radiotherapy allow Surgery Not specify Other No concurrent standard investigational treatment leukemia No concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>